Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$671.96K$671.96Kderived+38.0% vs Q4 2022 Net Income-$1.17M-$1.17MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,255,667N/M Operating Cash Flowderived-$793,027N/M Margins · derivedOperating margin-186.9%+134.2 pt vs Q4 2022
Net margin-174.3%+130.1 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 21, 2024 · 81 d after period end